Table 2.
Influence of clinicopathological characteristics on patients’ prognosis by Kaplan-Meier analysis
| Variables | n | DFS | OS | P | |||||
|---|---|---|---|---|---|---|---|---|---|
| 1-yr | 3-yr | 5-yr | P | 1-yr | 3-yr | 5-yrs | |||
| Gender | |||||||||
| Male | 240 | 41.7% | 29.2% | 25.3% | 66.7% | 43.8% | 37.1% | ||
| Female | 31 | 54.8% | 38.7% | 38.7% | 0.095 | 83.9% | 61.3% | 54.8% | 0.034 |
| Age (years) | |||||||||
| ≤ 50 | 131 | 41.2% | 31.3% | 28.2% | 67.2% | 45.0% | 37.4% | ||
| > 50 | 140 | 48.6% | 29.3% | 25.4% | 0.565 | 70.0% | 46.4% | 40.7% | 0.619 |
| HCC family history | |||||||||
| Yes | 18 | 50.0% | 27.8% | 22.2% | 83.3% | 55.6% | 55.6% | ||
| No | 253 | 42.7% | 30.4% | 27.1% | 0.864 | 67.6% | 45.1% | 37.9% | 0.148 |
| HBsAg | |||||||||
| Negative | 32 | 59.4% | 37.5% | 37.5% | 78.1% | 50.0% | 43.8% | ||
| Positive | 239 | 41.0% | 29.3% | 25.3% | 0.148 | 67.4% | 45.2% | 38.5% | 0.366 |
| Child-pugh stage | |||||||||
| A | 269 | 43.1% | 30.1% | 26.6% | 68.8% | 45.7% | 39.0% | ||
| B | 2 | 50.0% | 50.0% | 50.0% | 0.485 | 50.0% | 50.0% | 50.0% | 0.799 |
| AFP (ng/ml) | |||||||||
| ≤ 20 | 67 | 55.2% | 35.8% | 34.3% | 73.1% | 52.2% | 47.8% | ||
| > 20 | 204 | 39.2% | 28.4% | 24.3% | 0.078 | 67.2% | 43.6% | 36.2% | 0.063 |
| Edmondson grading | |||||||||
| I-II | 212 | 47.6% | 34.4% | 30.5% | 71.7% | 49.5% | 43.8% | ||
| III-IV | 59 | 27.1% | 15.3% | 13.6% | < 0.001 | 57.6% | 32.2% | 22.0% | 0.002 |
| Tumor size (cm) | |||||||||
| ≤ 5 | 96 | 66.7% | 50.0% | 42.4% | 87.5% | 67.7% | 60.4% | ||
| > 5 | 175 | 29.7% | 19.4% | 18.3% | < 0.001 | 58.3% | 33.7% | 27.4% | < 0.001 |
| Liver Cirrhosis | |||||||||
| Absent | 55 | 41.8% | 30.9% | 27.3% | 76.4% | 47.3% | 41.8% | ||
| Present | 216 | 43.5% | 30.1% | 26.7% | 0.973 | 66.7% | 45.4% | 38.4% | 0.399 |
| Capsulation | |||||||||
| Capsulated | 171 | 53.8% | 37.4% | 35.6% | 78.4% | 55.0% | 49.1% | ||
| Non-caspulated | 100 | 25.0% | 18.0% | 11.6% | < 0.001 | 52.0% | 30.0% | 22.0% | < 0.001 |
| Tumor number | |||||||||
| Single | 185 | 51.9% | 38.4% | 34.0% | 75.7% | 55.1% | 49.7% | ||
| Multiple | 86 | 24.4% | 12.7% | 11.1% | < 0.001 | 53.5% | 25.6% | 16.3% | < 0.001 |
| Vascular invasion | |||||||||
| Yes | 56 | 12.5% | 7.1% | 5.4% | 32.1% | 16.1% | 8.9% | ||
| No | 215 | 51.2% | 36.3% | 32.4% | < 0.001 | 78.1% | 53.5% | 47.0% | < 0.001 |
| HRNR expression | |||||||||
| Low | 114 | 61.4% | 49.1% | 45.3% | 78.9% | 65.8% | 63.1% | ||
| High | 157 | 29.9% | 16.6% | 13.4% | < 0.001 | 61.1% | 31.2% | 21.6% | < 0.001 |
| TNM stage | |||||||||
| I-II | 152 | 59.9% | 44.7% | 40.6% | 84.9% | 63.2% | 57.9% | ||
| III-IV | 119 | 21.8% | 11.8% | 9.2% | < 0.001 | 47.9% | 23.5% | 15.1% | < 0.001 |
DFS disease-free survival, OS overall survival. Other abbreviations as in Table 1